Revolutionizing Cancer Treatment: Royal Marsden First to Use Adaptive Radiotherapy Technology

Royal Marsden Pioneers Adaptive Radiotherapy

In March 2025, The Royal Marsden NHS Foundation Trust emerged as a beacon of hope in the battle against cancer. As the first medical center globally to utilize the new adaptive replanning module in RayStation, they have begun a revolutionary approach to online adaptive radiotherapy. This innovative technology promises to refine treatment processes and offer more personalized care for cancer patients.

The integration of RayStation's latest adaptive replanning capabilities allows oncologists at The Royal Marsden to tailor each treatment session in real-time based on the patient's current anatomical needs. The inaugural patient treated with this groundbreaking module had endometrial cancer and received care using the Radixact linear accelerator. The combination of precise technology and a dedicated care team highlights the center's commitment to innovation and efficiency in cancer treatments.

Dr. Susan Lalondrelle, a Consultant Clinical Oncologist at The Royal Marsden, expressed pride in their pioneering achievement. She noted the profound impact of using advanced online adaptive radiotherapy technology. "Being able to adjust treatments while a patient lies on the treatment bed marks a significant advancement towards personalized oncology care," she remarked. This innovative therapy reflects The Royal Marsden’s ongoing mission to advance in cancer research and treatment methodologies, offering hope to countless patients.

Collaboration with RaySearch Laboratories

The collaboration between The Royal Marsden and RaySearch Laboratories is crucial in driving the next wave of advancements in cancer care. Johan Löf, CEO of RaySearch, acknowledged the significance of Royal Marsden's achievement: "Online adaptive has been a key focus for RaySearch for many years, and seeing our technology utilized in such a transformative manner is highly rewarding. We are excited to work with The Royal Marsden on further refining these systems to enhance clinical effectiveness."

With plans to integrate RayCare, RaySearch’s oncology information system, the teams aim to optimize treatment timelines and make patient care even more efficient. The commitment to improving how these sophisticated systems communicate serves as a foundational step towards a more integrated adaptive workflow.

Future of Adaptive Radiotherapy

The implications of this technological leap extend beyond The Royal Marsden’s walls. By adopting an online adaptive workflow, cancer centers across the globe utilizing RaySearch software can replicate this model regardless of their treatment setups. This broadens the potential of adaptive radiotherapy, allowing more clinics to implement advanced technologies in their operations.

The drive for the best patient outcomes is paramount at The Royal Marsden, evidenced by the significant backing from The Royal Marsden Cancer Charity. This charity ensures that healthcare professionals and researchers have the resources necessary to pioneer state-of-the-art treatments and improve patient environments, fostering an atmosphere where innovation can thrive.

About The Royal Marsden

Founded in 1851 as the world’s first dedicated cancer hospital, The Royal Marsden has grown into Europe’s largest cancer treatment center. Along with the Institute of Cancer Research (ICR), it remains at the forefront of cancer diagnosis and treatment, treating over 59,000 patients each year. The center’s reputation as a leader in groundbreaking research and technology adoption continues to set the standard for cancer care globally.

As they advance their operational capabilities with online adaptive radiotherapy, The Royal Marsden and RaySearch are not just enhancing treatment efficiency—they are also shaping the future of oncological care through a commitment to innovation, collaboration, and patient-centered practices.

With a comprehensive focus on continuing education and groundbreaking research, The Royal Marsden exemplifies what it truly means to be a leader in the cancer treatment space. This balance between clinical excellence and innovation is undoubtedly paving the way for future advancements in how cancer care is delivered not only in the UK but also around the world.